XML 158 R127.htm IDEA: XBRL DOCUMENT
v3.26.1

Off-balance sheet commitments given (Details) € in Thousands, $ in Thousands |  |  |  | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | ---
Dec. 16, 2016 EUR (€) | Dec. 16, 2013 EUR (€) | Nov. 11, 2006 USD ($) academic_institution | Dec. 31, 2025 EUR (€) | Dec. 31, 2024 EUR (€) | Dec. 31, 2023 EUR (€) | Jun. 02, 2017 EUR (€) | Dec. 04, 2008 license
Disclosure Of Off-Balance Sheet Commitments [Line Items] |  |  |  |  |  |  |  |
Repayments of conditional advances |  |  |  | € 0 | € 2,708 | € 110 |  |
Capital commitments |  |  |  | € 205,131 | 234,908 | € 201,777 |  |
CARENA conditional advance |  |  |  |  |  |  |  |
Disclosure Of Off-Balance Sheet Commitments [Line Items] |  |  |  |  |  |  |  |
Maximum drawdown capacity including interest |  | € 3,840 |  |  |  |  |  |
Annual percentage of proceeds from sale of intellectual property right |  | 50.00% |  |  |  |  |  |
Annual revenue from sale of products developed, period |  | 5 years |  |  |  |  |  |
Percentage of annual revenue from sale of products developed |  | 1.20% |  |  |  |  |  |
Repayments of conditional advances |  |  |  |  | € 234 |  |  |
Maximum drawdown capacity |  | € 3,840 |  |  |  |  |  |
CARENA conditional advance | Minimum |  |  |  |  |  |  |  |
Disclosure Of Off-Balance Sheet Commitments [Line Items] |  |  |  |  |  |  |  |
Pre-tax revenue threshold |  | 50,000 |  |  |  |  |  |
CARENA conditional advance | Maximum |  |  |  |  |  |  |  |
Disclosure Of Off-Balance Sheet Commitments [Line Items] |  |  |  |  |  |  |  |
Annual revenue from sale of products developed |  | € 6,800 |  |  |  |  |  |
Repayment period |  | 15 years |  |  |  |  |  |
RNP-VIR conditional advance |  |  |  |  |  |  |  |
Disclosure Of Off-Balance Sheet Commitments [Line Items] |  |  |  |  |  |  |  |
Maximum drawdown capacity including interest | € 6,576 |  |  |  |  |  |  |
Annual percentage of proceeds from sale of intellectual property right | 50.00% |  |  |  |  |  |  |
Annual revenue from sale of products developed, period | 5 years |  |  |  |  |  |  |
Percentage of annual revenue from sale of products developed | 3.00% |  |  |  |  |  |  |
Maximum drawdown capacity | € 6,300 |  |  |  |  |  |  |
RNP-VIR conditional advance | Minimum |  |  |  |  |  |  |  |
Disclosure Of Off-Balance Sheet Commitments [Line Items] |  |  |  |  |  |  |  |
Pre-tax revenue threshold | 25,000 |  |  |  |  |  |  |
RNP-VIR conditional advance | Maximum |  |  |  |  |  |  |  |
Disclosure Of Off-Balance Sheet Commitments [Line Items] |  |  |  |  |  |  |  |
Annual revenue from sale of products developed | € 5,500 |  |  |  |  |  |  |
Repayment period | 15 years |  |  |  |  |  |  |
Ebola conditional advance |  |  |  |  |  |  |  |
Disclosure Of Off-Balance Sheet Commitments [Line Items] |  |  |  |  |  |  |  |
Maximum drawdown capacity |  |  |  |  |  |  | € 390 |
Ebola conditional advance, BPI Languedoc-Roussillon |  |  |  |  |  |  |  |
Disclosure Of Off-Balance Sheet Commitments [Line Items] |  |  |  |  |  |  |  |
Maximum drawdown capacity |  |  |  |  |  |  | 130 |
Ebola conditional advance, BPI France |  |  |  |  |  |  |  |
Disclosure Of Off-Balance Sheet Commitments [Line Items] |  |  |  |  |  |  |  |
Maximum drawdown capacity |  |  |  |  |  |  | € 260 |
The Scripps Research Institute, University of Chicago and Brigham Young University |  |  |  |  |  |  |  |
Disclosure Of Off-Balance Sheet Commitments [Line Items] |  |  |  |  |  |  |  |
Proportion of ownership interests held by non-controlling interests |  |  |  | 0.41% |  |  |  |
Exclusive licensing agreement with CNRS, University of Montpellier and Institut Curie |  |  |  |  |  |  |  |
Disclosure Of Off-Balance Sheet Commitments [Line Items] |  |  |  |  |  |  |  |
Number of exclusive licenses | license |  |  |  |  |  |  |  | 4
Exclusive licensing contract with the Scripps Research Institute, University of Chicago and Brigham Young University |  |  |  |  |  |  |  |
Disclosure Of Off-Balance Sheet Commitments [Line Items] |  |  |  |  |  |  |  |
Potential development milestone payment, IND filing | $ |  |  | $ 50 |  |  |  |  |
Potential development milestone payment, phase 3 | $ |  |  | 300 |  |  |  |  |
Potential development milestone payment, IND approval | $ |  |  | $ 500 |  |  |  |  |
Number of academic institutions | academic_institution |  |  | 3 |  |  |  |  |

X
- Definition Collaboration Agreements, Potential Development Milestone Payment, IND Approval + References No definition available. + Details
Name: | abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreements, Potential Development Milestone Payment, IND Filing + References No definition available. + Details
Name: | abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreements, Potential Development Milestone Payment, Phase 3 + References No definition available. + Details
Name: | abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Disclosure Of Off-Balance Sheet Commitments [Line Items] + References No definition available. + Details
Name: | abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems
Namespace Prefix: | abvx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Academic Institutions + References No definition available. + Details
Name: | abvx_NumberOfAcademicInstitutions
Namespace Prefix: | abvx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Exclusive Licenses + References No definition available. + Details
Name: | abvx_NumberOfExclusiveLicenses
Namespace Prefix: | abvx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Other Financial Liabilities, Annual Percentage Of Proceeds From Sale Of Intellectual Property Right + References No definition available. + Details
Name: | abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight
Namespace Prefix: | abvx_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Other Financial Liabilities, Annual Revenue From Sale Of Products Developed, Period + References No definition available. + Details
Name: | abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod
Namespace Prefix: | abvx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other Financial Liabilities, Maximum Drawdown Capacity + References No definition available. + Details
Name: | abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Other Financial Liabilities, Maximum Drawdown Capacity Including Interest + References No definition available. + Details
Name: | abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Other Financial Liabilities, Payable, Annual Revenue From Sale Of Products Developed + References No definition available. + Details
Name: | abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Other Financial Liabilities, Percentage Of Annual Revenue From Sale Of Products Developed + References No definition available. + Details
Name: | abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped
Namespace Prefix: | abvx_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Other Financial Liabilities, Percentage Of Annual Revenue From Sale Of Products Developed, Pre-Tax Revenue Threshold + References No definition available. + Details
Name: | abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Other Financial Liabilities, Repayment Period + References No definition available. + Details
Name: | abvx_OtherFinancialLiabilitiesRepaymentPeriod
Namespace Prefix: | abvx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Repayments Of Conditional Advances + References No definition available. + Details
Name: | abvx_RepaymentsOfConditionalAdvances
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of future capital expenditures that the entity is committed to make. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Note Expiry date 2027-01-01 -Name IAS -Number 1 -IssueDate 2025-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_CapitalCommitments
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Total for all subsidiaries [member]; Non-controlling interests] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph 12 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_c&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPIFranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | abvx_PrincipalAgreementsAxis=abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | abvx_PrincipalAgreementsAxis=abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |